(Q24239973)

1

0 references

Miguel M. Coelho

object named as

Miguel M Coelho

3

0 references

Joaquim Ferreira

object named as

Joaquim Ferreira

2

0 references

author name string

Mário Rosa

Cochrane Database of Systematic Reviews

4

0 references

publication date

8 July 2009

0 references

published in

0 references

cites work

Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

A controlled trial of idebenone in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Motor and cognitive improvements in patients with Huntington's disease after neural transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Creatine supplementation lowers brain glutamate levels in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Minocycline for Huntington's disease: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Neuroprotection in Huntington's disease: a 2-year study on minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Bilateral human fetal striatal transplantation in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Riluzole therapy in Huntington's disease (HD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Huntington's disease: present treatments and future therapeutic modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Trinucleotide repeat length and progression of illness in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

George Huntington and hereditary chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006455.PUB2

The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

21 January 2018

1 reference

12 December 2020

Riluzole in Huntington's disease: a 3-year, randomized controlled study

1 reference

12 December 2020

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

12 December 2020

Assessment of coenzyme Q10 tolerability in Huntington's disease

1 reference

12 December 2020

Trial of d-alpha-tocopherol in Huntington's disease

1 reference

12 December 2020

Vitamin E in treatment of Huntington's chorea

1 reference

12 December 2020

Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results

1 reference

12 December 2020